Previous close | 25.30 |
Open | N/A |
Bid | 25.15 |
Ask | 28.95 |
Strike | 50.00 |
Expiry date | 2024-05-17 |
Day's range | 25.30 - 25.30 |
Contract range | N/A |
Volume | |
Open interest | 63 |
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
The latest investor updates on stocks that are trending on Monday.
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb